Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ANIP

ANI Pharmaceuticals Inc

Oct 30 • 04:00PM ET

91.93

-0.30 -0.33 %

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Peers: AMGN REGN VRTX BIIB GILD ILMN BMRN INCY NBIX UTHR

| Held by: IJR VTI IWM VXF IWO SPSM IJT VTWO SLYG SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.77	Insider Own	13.85%	Shs Outstand	21.72M	Perf Week	-3.13%
Market Cap	1.99B	Forward P/E	11.41	EPS next Y	8.06	Insider Trans	-12.28%	Shs Float	18.69M	Perf Month	1.95%
Enterprise Value	2.42B	PEG	-	EPS next Q	1.77	Inst Own	92.56%	Short Float	12.71%	Perf Quarter	43.80%
Income	-14.22M	P/S	2.67	EPS this Y	40.68%	Inst Trans	0.64%	Short Ratio	5.03	Perf Half Y	30.05%
Sales	747.40M	P/B	4.57	EPS next Y	10.13%	ROA	-1.11%	Short Interest	2.38M	Perf YTD	66.30%
Book/sh	20.10	P/C	8.92	EPS next 5Y	21.12%	ROE	-2.82%	52W High	99.50 -7.61%	Perf Year	58.60%
Cash/sh	10.30	P/FCF	15.90	EPS past 3/5Y	32.54% -	ROIC	-1.33%	52W Low	52.50 75.10%	Perf 3Y	151.11%
Dividend Est.	-	EV/EBITDA	25.33	Sales past 3/5Y	41.66% 24.36%	Gross Margin	49.76%	Volatility	3.54% 2.97%	Perf 5Y	217.55%
Dividend TTM	-	EV/Sales	3.23	EPS Y/Y TTM	-160.14%	Oper. Margin	1.46%	ATR (14)	2.76	Perf 10Y	146.20%
Dividend Ex-Date	-	Quick Ratio	1.96	Sales Y/Y TTM	38.68%	Profit Margin	-1.90%	RSI (14)	47.78	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	2.54	EPS Q/Q	359.25%	SMA20	-0.27%	Beta	0.54	Target Price	107.00
Payout	-	Debt/Eq	1.48	Sales Q/Q	53.12%	SMA50	-1.68%	Rel Volume	0.41	Prev Close	92.23
Employees	897	LT Debt/Eq	1.45	Earnings	Nov 07 BMO	SMA200	27.46%	Avg Volume	472.33K	Price	91.93
IPO	May 12, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	28.05% 11.18%	Trades		Volume	193,771	Change	-0.33%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Initiated	H.C. Wainwright	Buy	$84
Mar-14-25	Initiated	Jefferies	Buy	$80
Mar-12-25	Initiated	JP Morgan	Overweight	$85
Dec-11-24	Initiated	Leerink Partners	Outperform	$80
Oct-11-24	Initiated	Piper Sandler	Overweight	$68
Mar-15-24	Initiated	CapitalOne	Overweight	$80
Aug-22-23	Reiterated	H.C. Wainwright	Buy	$60 → $73
Mar-01-23	Initiated	Guggenheim	Buy	$55
Sep-07-22	Initiated	H.C. Wainwright	Buy	$50
Nov-02-21	Initiated	Truist	Buy	$70
May-07-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-19	Initiated	Guggenheim	Buy
May-10-19	Downgrade	Raymond James	Strong Buy → Outperform	$73 → $82
Oct-16-17	Reiterated	Canaccord Genuity	Buy	$60 → $66
Jul-31-17	Initiated	Canaccord Genuity	Buy	$60
Feb-22-17	Downgrade	ROTH Capital	Buy → Neutral
Jun-23-16	Initiated	Raymond James	Strong Buy	$68
May-24-16	Downgrade	Standpoint Research	Buy → Hold
Nov-13-15	Initiated	Standpoint Research	Buy	$54
Sep-28-15	Upgrade	ROTH Capital	Neutral → Buy	$67 → $60

Show Previous Ratings

Oct-30-25 01:14PM	Cigna Q3 Earnings Beat Estimates on Evernorth Health Unit Strength (Zacks)
12:41PM	MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down (Zacks)
12:08PM	Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down (Zacks)
Oct-29-25 01:45PM	Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised (Zacks)
11:59AM	Centene Q3 Earnings Beat Estimates on Increasing Premium (Zacks)
11:24AM	Loading…
11:24AM	United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
11:18AM	RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down (Zacks)
Oct-28-25 01:18PM	UnitedHealth Q3 Earnings Beat on Rising Commercial Membership (Zacks)
11:09AM	INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales (Zacks)
Oct-27-25 12:45PM	Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
12:44PM	ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)
09:40AM	Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year? (Zacks)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
08:34AM	3 Profitable Stocks We're Skeptical Of (StockStory)
Oct-24-25 01:01PM	HCA Q3 Earnings Beat Estimates on Rising Inpatient Surgery Cases (Zacks)
12:34PM	Loading…
12:34PM	Community Health Q3 Earnings Beat on Rising Same-Store Admissions (Zacks)
08:53AM	Here's How Charles River Stock Is Placed Ahead of Q3 Earnings (Zacks)
06:50AM	ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET (GlobeNewswire)
Oct-23-25 01:04PM	Molina Healthcare Q3 Earnings Miss Estimates on Rising Expenses (Zacks)
08:07AM	Here's How Henry Schein Is Placed Ahead of Q3 Earnings (Zacks)
07:54AM	Bio-Techne Q1 Earnings Preview: What's in Store for the Stock? (Zacks)
Oct-22-25 12:35PM	Will This Drug Stock Explode After Earnings Like Last Quarter? (Investor's Business Daily)
12:34PM	Will This Drug Stock Explode After Earnings As It Did Last Quarter? (Investor's Business Daily)
11:04AM	NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board (Zacks)
10:18AM	SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study (Zacks)
09:20AM	BFLY Q3 Earnings Preview: Strategic Progress Likely to Support Growth (Zacks)
08:40AM	STERIS to Report Q2 Earnings: Here's What to Expect (Zacks)
Oct-21-25 02:05PM	Elevance Health Q3 Earnings Beat Estimates on Strong MA Membership (Zacks)
09:34AM	Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis (Zacks)
09:30AM	NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients (Zacks)
08:56AM	Loading…
08:56AM	Zimmer Biomet to Report Q3 Earnings: Here's What to Expect (Zacks)
Oct-20-25 08:57AM	ALGN Gears Up for Q3 Earnings: What Lies Ahead for the Stock? (Zacks)
08:42AM	Here's How IDEXX Laboratories is Placed Ahead of Q3 Earnings (Zacks)
Oct-17-25 11:52AM	ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up (Zacks)
11:44AM	NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs (Zacks)
08:26AM	Robust TAVR Growth to Drive Edwards Lifesciences' Q3 Earnings (Zacks)
Oct-16-25 12:00PM	ANI (ANIP) Upgraded to Strong Buy: Here's Why (Zacks)
11:14AM	Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan (Zacks)
08:49AM	TMO to Report Q3 Earnings: Life Science Solutions Segment in Focus (Zacks)
08:46AM	Will Robust Cardiovascular Performance Fuel BSX's Q3 Earnings? (Zacks)
06:50AM	ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting (GlobeNewswire)
Oct-15-25 12:10PM	Why ANI (ANIP) Could Beat Earnings Estimates Again (Zacks)
11:35AM	CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer (Zacks)
11:31AM	RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
08:40AM	Labcorp Gears Up to Report Q3 Earnings: What's in Store for the Stock? (Zacks)
Oct-14-25 08:38AM	Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings (Zacks)
Oct-10-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP) (Zacks)
09:40AM	Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? (Zacks)
08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Oct-09-25 10:57AM	BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers (Zacks)
09:48AM	Brookdale Posts Strong YoY Rise in September 2025 Occupancy (Zacks)
Oct-07-25 12:04AM	ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Sep-29-25 02:36PM	AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease (Zacks)
Sep-25-25 09:59AM	HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal (Zacks)
Sep-24-25 02:15PM	Humana Extends TailorCare Tie-Up to Enhance MA Member Health (Zacks)
12:45PM	Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
09:43AM	BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study (Zacks)
09:40AM	Is Clover Health Investments (CLOV) Outperforming Other Medical Stocks This Year? (Zacks)
04:47AM	Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience (Zacks)
Sep-23-25 09:23AM	5 Biotech Stocks Worth Adding to Your Portfolio Now (Zacks)
Sep-18-25 09:17AM	Biogen Gets EU Nod for First Postpartum Depression Drug (Zacks)
Sep-17-25 09:38AM	INCY Announces New Late-Stage Data on Skin Disease Drug (Zacks)
Sep-15-25 12:42PM	PBYI Surges 30% in 3 Months: How Should You Play the Stock? (Zacks)
Sep-12-25 11:36AM	JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
Sep-08-25 05:08PM	3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP) (Zacks)
04:59PM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks)
04:34PM	ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-02-25 04:06AM	ANI Pharmaceuticals, Inc. (ANIP) Hits Milestone with Cortrophin Gel Prefilled Syringe Launch (Insider Monkey)
Sep-01-25 11:36PM	Generic Pharmaceuticals Stocks Q2 Earnings: ANI Pharmaceuticals (NASDAQ:ANIP) Best of the Bunch (StockStory)
10:31AM	Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi (Zacks)
Aug-29-25 11:13AM	J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure (Zacks)
09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-28-25 12:00PM	ANI Pharmaceuticals (ANIP) is a Great Momentum Stock: Should You Buy? (Zacks)
Aug-26-25 09:17AM	IOVA Stock Drops 6% on $350M Common Stock Offering (Zacks)
Aug-25-25 04:30PM	ANI Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-22-25 12:45PM	Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
09:55AM	GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo (Zacks)
09:40AM	Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-15-25 01:31AM	The 5 Most Interesting Analyst Questions From ANI Pharmaceuticals's Q2 Earnings Call (StockStory)
Aug-11-25 10:00AM	ANIP Q2 Deep Dive: Rare Disease Expansion Fuels Outperformance, Generics Maintain Solid Trajectory (StockStory)
09:30AM	ANI (ANIP) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
Aug-09-25 03:05AM	ANI Pharmaceuticals Inc (ANIP) Q2 2025 Earnings Call Highlights: Record Revenue and Raised ... (GuruFocus.com)
Aug-08-25 12:21PM	Why ANI Pharmaceuticals (ANIP) Stock Is Up Today (StockStory) +18.07%
08:00AM	ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates (Zacks)
08:00AM	CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	ANI Pharmaceuticals's (NASDAQ:ANIP) Q2: Strong Sales, Stock Soars (StockStory)
06:58AM	ANI: Q2 Earnings Snapshot (Associated Press Finance)
06:50AM	ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance (GlobeNewswire)
Aug-07-25 05:50PM	Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-06-25 11:01PM	ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect (StockStory)
Aug-01-25 06:50AM	ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET (GlobeNewswire)
Jul-31-25 08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Jul-30-25 10:00AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-29-25 04:05PM	Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals (GlobeNewswire)
10:00AM	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
08:40AM	Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-24-25 05:50AM	ANI Pharmaceuticals reports outcomes from diabetic macular oedema trial (Clinical Trials Arena)
Jul-23-25 06:50AM	ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN for Use in Patients with Diabetic Macular Edema (DME) (GlobeNewswire)

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Oct 13 '25	Sale	90.09	400	36,036	75,674	Oct 14 07:49 PM
Davis Krista	SVP, CHIEF HR OFFICER	Sep 19 '25	Sale	98.04	1,000	98,040	60,186	Sep 22 05:14 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Sep 12 '25	Sale	98.42	400	39,368	76,074	Sep 15 07:16 PM
Pera Antonio R	Director	Sep 03 '25	Sale	94.94	7,292	692,302	22,660	Sep 04 04:44 PM
ANTONIO R PERA	Director	Sep 03 '25	Proposed Sale	94.94	7,292	692,270		Sep 03 04:03 PM
Leonard Matthew J	Director	Aug 25 '25	Sale	90.62	2,528	229,087	6,864	Aug 26 06:19 PM
MATTHEW LEONARD	Director	Aug 25 '25	Proposed Sale	90.62	2,528	229,076		Aug 25 05:00 PM
Davis Krista	SVP, CHIEF HR OFFICER	Aug 22 '25	Sale	91.10	1,763	160,609	62,896	Aug 25 04:19 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Aug 21 '25	Sale	90.44	52,988	4,792,235	431,920	Aug 22 06:10 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Aug 20 '25	Sale	90.27	47,012	4,243,773	484,908	Aug 22 06:10 PM
Shanmugam Muthusamy	Officer	Aug 21 '25	Proposed Sale	90.44	52,988	4,792,058		Aug 21 04:26 PM
Shanmugam Muthusamy	Officer	Aug 20 '25	Proposed Sale	90.27	47,012	4,243,703		Aug 20 04:58 PM
Thoma Jeanne	Director	Aug 18 '25	Sale	89.15	21,540	1,920,370	23,405	Aug 20 04:42 PM
Pera Antonio R	Director	Aug 20 '25	Sale	89.73	5,421	486,426	29,952	Aug 20 04:41 PM
ANTONIO R PERA	Director	Aug 20 '25	Proposed Sale	89.73	5,421	486,407		Aug 20 04:02 PM
JEANNE THOMA	Director	Aug 18 '25	Proposed Sale	88.87	14,675	1,304,170		Aug 19 05:47 PM
Leonard Matthew J	Director	Aug 18 '25	Sale	88.17	6,937	611,635	9,392	Aug 18 05:23 PM
Walsh Patrick D	Director	Aug 15 '25	Sale	89.05	9,000	801,450	70,048	Aug 18 04:34 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Aug 15 '25	Sale	87.15	52,990	4,618,078	531,920	Aug 18 04:32 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Aug 14 '25	Sale	89.48	47,010	4,206,455	584,910	Aug 18 04:32 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Aug 15 '25	Sale	86.97	20,000	1,739,400	173,226	Aug 18 04:29 PM
JEANNE A THOMA	Director	Aug 18 '25	Proposed Sale	89.76	6,865	616,224		Aug 18 04:19 PM
MATTHEW LEONARD	Director	Aug 18 '25	Proposed Sale	88.17	6,937	611,644		Aug 18 04:18 PM
AMPERSAND 2020 LIMITED PARTNER	Director	Aug 18 '25	Proposed Sale	88.32	29,580	2,612,420		Aug 18 04:17 PM
PATRICK WALSH	Director	Aug 15 '25	Proposed Sale	89.05	9,000	801,450		Aug 15 04:27 PM
AMPERSAND 2020 LIMITED PARTNER	Director	Aug 15 '25	Proposed Sale	86.44	91,000	7,866,268		Aug 15 04:26 PM
Shanmugam Muthusamy	Officer	Aug 15 '25	Proposed Sale	87.15	52,990	4,618,064		Aug 15 04:04 PM
Rowland Thomas Andrew	SVP, HEAD - ESTABLISHED BRANDS	Aug 12 '25	Sale	85.71	4,975	426,407	40,794	Aug 14 05:53 PM
Lalwani Nikhil	PRESIDENT & CEO	Aug 12 '25	Sale	85.93	56,960	4,894,573	411,219	Aug 14 05:48 PM
Gutwerg Ori	SVP, GENERICS	Aug 12 '25	Sale	86.53	5,873	508,191	84,024	Aug 14 05:46 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Aug 13 '25	Sale	88.87	400	35,548	76,474	Aug 14 05:43 PM
CAREY STEPHEN P.	SVP & CFO	Aug 12 '25	Option Exercise	46.49	50,000	2,324,500	230,863	Aug 14 05:40 PM
CAREY STEPHEN P.	SVP & CFO	Aug 12 '25	Sale	86.07	50,000	4,303,500	180,863	Aug 14 05:40 PM
HAUGHEY THOMAS	Director	Aug 12 '25	Sale	85.93	19,341	1,661,972	36,521	Aug 14 05:38 PM
Shanmugam Muthusamy	Officer	Aug 14 '25	Proposed Sale	89.48	47,010	4,206,604		Aug 14 04:56 PM
NIKHIL S LALWANI	Officer	Aug 12 '25	Proposed Sale	85.93	56,960	4,894,823		Aug 12 06:04 PM
THOMAS HAUGHEY	Director	Aug 12 '25	Proposed Sale	85.93	19,341	1,662,048		Aug 12 05:16 PM
STEPHEN P CAREY	Officer	Aug 12 '25	Proposed Sale	86.07	50,000	4,303,590		Aug 12 04:15 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jul 14 '25	Sale	64.88	400	25,952	78,945	Jul 14 04:11 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jun 13 '25	Sale	61.37	400	24,548	79,345	Jun 16 05:24 PM
Gutwerg Ori	SVP, GENERICS	May 15 '25	Sale	60.07	881	52,922	89,897	May 16 04:57 PM
Mutz Christopher	HEAD OF RARE DISEASE	May 14 '25	Sale	60.45	4,000	241,800	107,317	May 15 08:10 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	May 13 '25	Sale	62.20	400	24,880	79,745	May 13 04:29 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 09 '25	Sale	76.83	700	53,781	631,920	May 13 04:21 PM
Shanmugam Muthusamy	Officer	May 09 '25	Proposed Sale	76.77	700	53,740		May 12 08:50 AM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Apr 14 '25	Sale	68.96	400	27,584	80,145	Apr 14 04:17 PM
Davis Krista	SVP, CHIEF HR OFFICER	Mar 19 '25	Sale	65.00	1,866	121,290	64,659	Mar 20 04:14 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Mar 13 '25	Sale	63.33	400	25,332	80,545	Mar 14 05:28 PM
Davis Krista	SVP, CHIEF HR OFFICER	Mar 07 '25	Sale	60.86	1,000	60,860	66,525	Mar 10 08:28 PM
Gutwerg Ori	SVP, GENERICS	Mar 05 '25	Option Exercise	31.49	300	9,447	99,476	Mar 07 04:09 PM
Gutwerg Ori	SVP, GENERICS	Mar 05 '25	Sale	60.00	5,384	323,049	94,092	Mar 07 04:09 PM
Davis Krista	SVP, CHIEF HR OFFICER	Feb 21 '25	Sale	60.20	1,000	60,200	68,624	Feb 24 04:33 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Feb 13 '25	Sale	59.54	400	23,816	83,478	Feb 18 08:12 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jan 13 '25	Sale	53.92	400	21,568	55,588	Jan 13 04:15 PM
CAREY STEPHEN P.	SVP & CFO	Dec 17 '24	Sale	55.79	7,500	418,425	154,468	Dec 18 05:59 PM
CAREY STEPHEN P.	Officer	Dec 17 '24	Proposed Sale	55.25	7,500	414,375		Dec 17 05:35 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Dec 13 '24	Sale	56.24	250	14,060	55,988	Dec 16 04:20 PM
Davis Krista	SVP, CHIEF HR OFFICER	Dec 11 '24	Sale	60.00	1,000	60,000	49,059	Dec 12 05:08 PM
Lalwani Nikhil	PRESIDENT & CEO	Nov 26 '24	Option Exercise	29.00	30,000	870,000	403,859	Nov 27 05:38 PM
Lalwani Nikhil	PRESIDENT & CEO	Nov 26 '24	Sale	57.99	33,481	1,941,442	370,378	Nov 27 05:38 PM
Lalwani Nikhil	Officer	Nov 26 '24	Proposed Sale	57.99	33,481	1,941,484		Nov 26 07:44 PM
Mutz Christopher	HEAD OF RARE DISEASE	Nov 15 '24	Sale	57.70	6,500	375,050	76,777	Nov 18 04:03 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Nov 13 '24	Sale	61.36	250	15,340	56,238	Nov 14 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANIP

ANI Pharmaceuticals Inc

Upgrade your FINVIZ experience